"},"content":{"rendered":"<\/p>\n
<\/p>\n
Last Friday, Danish pharmaceutical company Novo Nordisk<\/strong> pulled off a masterstroke by surpassing the market capitalization of LVMH<\/strong>, the French luxury goods giant, thus establishing its position as Europe’s largest listed company. According to Factset, Novo Nordisk’s market capitalization reached DKK 2,934 billion, or around \u20ac393.7 billion<\/strong> at the close of trading, surpassing LVMH’s \u20ac389.5 billion<\/strong>.<\/p>\n <\/p>\n Novo Nordisk’s rise to prominence has been spectacular, impressing investors for several months. Its recent quarterly results have been fuelled by exceptional growth in sales of its obesity treatments, recording an increase of 157%<\/strong> in the first half of 2023 compared with the same period last year. This impressive growth also led the company to revise upwards its annual sales forecasts in early August. Currently ranked 17th worldwide in terms of market capitalization, Novo Nordisk is just behind JPMorgan Chase<\/strong>, far behind the giant Apple<\/strong>, which is closing in on $3,000 billion<\/strong> in market capitalization.<\/p>\n <\/p>\n For LVMH, this defeat marks the end of its position as European market capitalization leader, which it had held since February 2021<\/strong>. Last January, LVMH had even passed the symbolic 400 billion euro<\/strong> mark, a historic feat for a European company. However, since the beginning of the year, LVMH shares have struggled to regain momentum, largely due to the Chinese economic recovery which, after the lifting of restrictions linked to the COVID-19 pandemic, has failed to meet economists’ expectations.<\/p>\n <\/p>\n The epic duel between Novo Nordisk and LVMH for the crown of Europe’s largest capitalization shows how quickly stock market fortunes can change. LVMH had previously dethroned Nestl\u00e9<\/strong> in early 2021 to become Europe’s market capitalization leader.<\/p>\n <\/p>\n\u2028\u2028\t\tNew leader<\/h2>\n